{"url_path":"/sec/rajaf/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 Quantitative and Qualitative Disclosures About Market Risk**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885680/0001213900-26-057774-index.html","accession_number":"0001213900-26-057774","cik":"0001885680","ticker":"RAJAF","issuer_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885680/0001213900-26-057774-index.html","primary_entity_key":"0001885680","primary_entity_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd."},"word_count":143,"has_tables":true,"body_markdown":"**Item\n11. Quantitative and Qualitative Disclosures About Market Risk**\n\n \n\n*Foreign Exchange Risk*\n\n* *\n\nSome of our revenues and expenses are denominated\nsome are in NTD. In our consolidated financial statements, our financial information that uses NTD as the functional currency has been\ntranslated into U.S. dollars. We do not believe that we currently have any significant direct foreign exchange risk and have not used\nany derivative financial instruments to hedge exposure to such risk.\n\n \n\n*Inflation Risk*\n\n** **\n\nWe are also exposed to inflation risk. Inflationary\nfactors, such as increases in labor costs, could impair our operating results. Although we do not believe that inflation has had a material\nimpact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on\nour ability to maintain current levels of gross margin and operating expenses."}